| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_84d9adaa7e7ce01ce8020f5c721aba10 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P- |
| filingDate |
2001-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ad8817bfeb63c122d3ebd778e846ba8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f058cd9da94db24e3298394667709c0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a30d95b81667c16871fb3fe504438819
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1aa52964884d2141378f9cd0c92ea4f7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_481179613a8ce72ecb726bbbb371c2f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4230b234e5ded808e3561f57c3c8075b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf8bf70beaa737024e575d702862010c |
| publicationDate |
2003-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
HU-0302675-A2 |
| titleOfInvention |
New crystalline modifications of lopinavir |
| abstract |
SUMMARY OF THE INVENTION The present invention relates to the hydrated crystal modification of lopinavir (A), the solvated crystal modification of lopinavir, and the modification of non-solvated crystal of alopinavir. SUMMARY OF THE INVENTION The present invention relates to a solvated crystal modification of lopinavir having a peak in the solid phase infrared spectrum in the 1661-1673 cm-1 range and having a peak in the 1645-1653 cm-1 range and having a peak in the 1619-1629 cm-1 range. The invention also relates to the non-solvated crystal modification of lopinavir. The lopinavir crystal modifications can be used to purify and isolate lopinavir. HE |
| priorityDate |
2000-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |